Literature DB >> 14676992

The effect of 1-year transdermal estrogen replacement therapy on bone mineral density and biochemical markers of bone turnover in osteopenic postmenopausal systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial.

H P Bhattoa1, P Bettembuk, A Balogh, G Szegedi, E Kiss.   

Abstract

We studied the effect of 1-year transdermal estrogen replacement therapy (ERT) on bone mineral density (BMD) and biochemical markers of bone turnover in osteopenic postmenopausal systemic lupus erythematosus (SLE) patients in a randomized, double-blind, placebo-controlled trial. SLE patients were randomly allocated to treatment (estradiol; 50 microg transdermal 17beta-estradiol; n=15) or placebo ( n=17) group. Both groups received 5 mg continuous oral medroxyprogesterone acetate, 500 mg calcium and 400 IU vitamin D(3). L(1)-L(4) spine (LS), left femur and total hip BMD were measured at baseline and at 6 and 12 months. Serum osteocalcin (OC) and degradation products of C-terminal telopeptides of type-I collagen (CTx) levels were measured at baseline and 3, 6, 9, and 12 months. There was a significant difference in the percentage change of LS BMD at 6 months between the two groups (103.24+/-3.74% (estradiol group) vs 98.99+/-3.11% (placebo group); P<0.005). There was a significant decrease within the estradiol group in the CTx levels between baseline and all subsequent visits ( P<0.05). There was no significant difference in SLE disease activity index, Systemic Lupus International Collaborating Clinics/American College of Rheumatology (ACR) damage index and corticosteroid dose during the study period. Transdermal estradiol may prevent bone loss in postmenopausal SLE women at the lumbar spine and femur, with no increase in disease activity among postmenopausal SLE women receiving transdermal ERT. The high dropout rate (8/15) leads us to the conclusion that efficacy of HRT in a high-risk group such as SLE women can be attained only in a small number of patients, provided all inclusion/exclusion criteria are strictly adhered to.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14676992     DOI: 10.1007/s00198-003-1553-6

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  33 in total

1.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

2.  Use of exogenous estrogens in systemic lupus erythematosus.

Authors:  C C Mok; C S Lau; R W Wong
Journal:  Semin Arthritis Rheum       Date:  2001-06       Impact factor: 5.532

3.  Hormone replacement therapy in systemic lupus erythematosus.

Authors:  S Kreidstein; M B Urowitz; D D Gladman; J Gough
Journal:  J Rheumatol       Date:  1997-11       Impact factor: 4.666

4.  Osteopenia in young hypogonadal women with systemic lupus erythematosus receiving chronic steroid therapy: a randomized controlled trial comparing calcitriol and hormonal replacement therapy.

Authors:  A W Kung; T M Chan; C S Lau; R W Wong; S S Yeung
Journal:  Rheumatology (Oxford)       Date:  1999-12       Impact factor: 7.580

5.  Osteoporosis screening in systemic lupus erythematosus: impact of disease duration and organ damage.

Authors:  A Becker; R Fischer; W A Scherbaum; M Schneider
Journal:  Lupus       Date:  2001       Impact factor: 2.911

6.  Systemic lupus erythematosus survival in Hungary. Results from a single centre.

Authors:  E Kiss; N Regéczy; G Szegedi
Journal:  Clin Exp Rheumatol       Date:  1999 Mar-Apr       Impact factor: 4.473

7.  Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.

Authors:  B Ettinger; D M Black; B H Mitlak; R K Knickerbocker; T Nickelsen; H K Genant; C Christiansen; P D Delmas; J R Zanchetta; J Stakkestad; C C Glüer; K Krueger; F J Cohen; S Eckert; K E Ensrud; L V Avioli; P Lips; S R Cummings
Journal:  JAMA       Date:  1999-08-18       Impact factor: 56.272

8.  Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial.

Authors:  Michelle A Petri; Robert G Lahita; Ronald F Van Vollenhoven; Joan T Merrill; Michael Schiff; Ellen M Ginzler; Vibeke Strand; Arlene Kunz; Kenneth J Gorelick; Kenneth E Schwartz
Journal:  Arthritis Rheum       Date:  2002-07

9.  Safety of hormonal replacement therapy in postmenopausal patients with systemic lupus erythematosus.

Authors:  C C Mok; C S Lau; C T Ho; K W Lee; M Y Mok; R W Wong
Journal:  Scand J Rheumatol       Date:  1998       Impact factor: 3.641

Review 10.  The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus.

Authors:  D Gladman; E Ginzler; C Goldsmith; P Fortin; M Liang; M Urowitz; P Bacon; S Bombardieri; J Hanly; E Hay; D Isenberg; J Jones; K Kalunian; P Maddison; O Nived; M Petri; M Richter; J Sanchez-Guerrero; M Snaith; G Sturfelt; D Symmons; A Zoma
Journal:  Arthritis Rheum       Date:  1996-03
View more
  8 in total

1.  On some osteoporosis analyses.

Authors:  A D Tsakok
Journal:  Osteoporos Int       Date:  2005-08       Impact factor: 4.507

Review 2.  Bone health and systemic lupus erythematosus.

Authors:  Chin Lee; Rosalind Ramsey-Goldman
Journal:  Curr Rheumatol Rep       Date:  2005-12       Impact factor: 4.592

3.  Bone impairment assessed by HR-pQCT in juvenile-onset systemic lupus erythematosus.

Authors:  J A Paupitz; G L Lima; J C Alvarenga; R M Oliveira; E Bonfa; R M R Pereira
Journal:  Osteoporos Int       Date:  2015-12-22       Impact factor: 4.507

Review 4.  Estrogen and autoimmune disease.

Authors:  Sara E Walker
Journal:  Clin Rev Allergy Immunol       Date:  2011-02       Impact factor: 8.667

Review 5.  Bone health in systemic lupus erythematosus.

Authors:  Pantelis Panopalis; Jinoos Yazdany
Journal:  Curr Rheumatol Rep       Date:  2009-07       Impact factor: 4.592

Review 6.  Autoimmune diseases and reproductive aging.

Authors:  Riley Bove
Journal:  Clin Immunol       Date:  2013-02-28       Impact factor: 3.969

Review 7.  [Modern therapy for systemic lupus erythematosus].

Authors:  R Fischer-Betz; M Schneider
Journal:  Z Rheumatol       Date:  2007-12       Impact factor: 1.372

8.  Interventions for cutaneous disease in systemic lupus erythematosus.

Authors:  Cora W Hannon; Collette McCourt; Hermenio C Lima; Suephy Chen; Cathy Bennett
Journal:  Cochrane Database Syst Rev       Date:  2021-03-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.